Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.33 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933444 | 0.90 | HSD17B2 (0.37) | IRAK4HSD17B2HSD17B1PARP10PARP15 | |
| SCHEMBL24933011 | 0.89 | P2RX3 (0.39) | IRAK4HSD17B2HSD17B1FFAR4PDK2 | |
| SCHEMBL24933597 | 0.89 | IRAK4 (0.37) | IRAK4HSD17B2HSD17B1PARP10PARP15 | |
| SCHEMBL24933526 | 0.86 | PARP10 (0.35) | IRAK4HSD17B2HSD17B1PARP10PARP15 | |
| SCHEMBL24933705 | 0.85 | P2RX3 (0.39) | IRAK4HSD17B2HSD17B1SCN9A | |
| SCHEMBL24933257 | 0.85 | P2RX3 (0.39) | IRAK4HSD17B2HSD17B1SCN9A | |
| SCHEMBL24933550 | 0.85 | HSD17B2 (0.37) | IRAK4HSD17B2HSD17B1FFAR4WDR5 | |
| SCHEMBL24933404 | 0.84 | CHRNB4 (0.46) | — | |
| SCHEMBL24933724 | 0.84 | IRAK4 (0.45) | IRAK4HSD17B2HSD17B1 | |
| SCHEMBL24933220 | 0.84 | HSD17B2 (0.36) | HSD17B2HSD17B1FFAR4PDK2WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |